Achieve Life Sciences ACHV 深 沪
已收盘 09-19 16:00:00 美东时间
2.82
-0.050
-1.74%
华盛通- 最 高2.925
- 今 开2.86
- 成交量 177.09万股
- 最 低 2.81
- 昨 收 2.87
- 总市值 1.44亿
- 52周最高 5.31
- 市盈率 静 --
- 换手率 3.47%
- 52周最低 1.84
- 委 比 -79.29%
- 总股本 5110.50万
- 历史最高 970.00
- 量 比 2.25
- 振 幅 4.01%
- 历史最低 1.84
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Achieve Life Sciences Appoints Craig Donnelly To COO
- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking
09-18 20:32
Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer
<p>Achieve Life Sciences promoted Craig Donnelly to Chief Operations Officer to lead its operations and commercial strategy for the anticipated launch of cytisinicline, a smoking cessation treatment, in mid-late 2026. With over 25 years of biopharmaceutical expertise, Donnelly will ensure efficient manufacturing, supply chain optimization, and regulatory compliance. Achieve expects this to support its transition from late-stage development to com...
09-18 12:30
Achieve生命科学任命临时首席医疗官
Achieve生命科学公司（ACHV）早盘下跌4.6%。该公司任命医学博士马克·鲁宾斯坦（Mark Rubinstein， M.D．）担任临时首席医疗官，接...
09-12 23:46
Achieve Life Sciences Announces Leadership Change
Achieve Life Sciences ( ($ACHV) ) just unveiled an announcement. On September 5...
09-12 05:28
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. announced that its CEO, Rick Stewart, will participate in two upcoming conferences: the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and the Lake Street 9th Annual Best Ideas Growth Conference (BIG9) on September 11, 2025. Both events will take place in New York, NY. Achieve is focused on developing cytisinicline, a plant-based alkaloid for smoking cessation, and has submitted a New Dr...
09-02 12:30
HC Wainwright & Co. Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and announces Price Target of $12.
08-21 19:10
Achieve Life Sciences Advances Cytisinicline Development
Achieve Life Sciences ( ($ACHV) ) has released its Q2 earnings. Here is a break...
08-08 13:26
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Achieve Life Sciences Inc. announced its second-quarter 2025 financial results, highlighting the submission of a New Drug Application (NDA) for cytisinicline to the FDA, a strategic partnership with Omnicom for commercial launch, and a $49.3 million public offering to support further development. The company also met FDA long-term safety requirements and published Phase 3 trial results in the *Journal of the American Medical Association (JAMA) In...
08-07 11:30
Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference
Achieve Life Sciences, a late-stage specialty pharmaceutical company, announced its participation in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. CEO Rick Stewart will engage in a fireside chat on July 29 at 3:20 pm EDT. The company is focused on developing cytisinicline, a plant-based alkaloid, as a treatment for nicotine dependence and smoking cessation. Cytisinicline has received Breakthrough Therapy designation from the FDA ...
07-29 12:30
